Willard Joshua R, Barrow Breanne M, Zraika Sakeneh
Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way (151), Seattle, WA, 98108, USA.
Division of Metabolism, Endocrinology & Nutrition, Department of Medicine, University of Washington, Seattle, WA, USA.
Diabetologia. 2017 Apr;60(4):701-708. doi: 10.1007/s00125-016-4172-4. Epub 2016 Dec 8.
AIM/HYPOTHESIS: Neprilysin, a widely expressed peptidase, is upregulated in metabolically altered states such as obesity and type 2 diabetes. Like dipeptidyl peptidase-4 (DPP-4), neprilysin can degrade and inactivate the insulinotropic peptide glucagon-like peptide-1 (GLP-1). Thus, we investigated whether neprilysin deficiency enhances active GLP-1 levels and improves glycaemia in a mouse model of high fat feeding.
Nep and Nep mice were fed a 60% fat diet for 16 weeks, after which active GLP-1 and DPP-4 activity levels were measured, as were glucose, insulin and C-peptide levels during an OGTT. Insulin sensitivity was assessed using an insulin tolerance test.
High-fat-fed Nep mice exhibited elevated active GLP-1 levels (5.8 ± 1.1 vs 3.5 ± 0.8 pmol/l, p < 0.05) in association with improved glucose tolerance, insulin sensitivity and beta cell function compared with high-fat-fed Nep mice. In addition, plasma DPP-4 activity was lower in high-fat-fed Nep mice (7.4 ± 1.0 vs 10.7 ± 1.3 nmol ml min, p < 0.05). No difference in insulin:C-peptide ratio was observed between Nep and Nep mice, suggesting that improved glycaemia does not result from changes in insulin clearance.
CONCLUSIONS/INTERPRETATION: Under conditions of increased dietary fat, an improved glycaemic status in neprilysin-deficient mice is associated with elevated active GLP-1 levels, reduced plasma DPP-4 activity and improved beta cell function. Thus, neprilysin inhibition may be a novel treatment strategy for type 2 diabetes.
目的/假设:中性内肽酶是一种广泛表达的肽酶,在肥胖和2型糖尿病等代谢改变状态下上调。与二肽基肽酶-4(DPP-4)一样,中性内肽酶可降解并使促胰岛素肽胰高血糖素样肽-1(GLP-1)失活。因此,我们在高脂喂养的小鼠模型中研究了中性内肽酶缺乏是否会提高活性GLP-1水平并改善血糖。
给Nep 和Nep 小鼠喂食60%脂肪饮食16周,之后测量活性GLP-1和DPP-4活性水平,以及口服葡萄糖耐量试验(OGTT)期间的葡萄糖、胰岛素和C肽水平。使用胰岛素耐量试验评估胰岛素敏感性。
与高脂喂养的Nep 小鼠相比,高脂喂养的Nep 小鼠活性GLP-1水平升高(5.8±1.1对3.5±0.8 pmol/l,p<0.05),同时葡萄糖耐量、胰岛素敏感性和β细胞功能得到改善。此外,高脂喂养的Nep 小鼠血浆DPP-4活性较低(7.4±1.0对10.7±1.3 nmol ml min,p<0.05)。Nep 和Nep 小鼠之间的胰岛素:C肽比值未观察到差异,表明血糖改善并非由胰岛素清除率变化所致。
结论/解读:在饮食脂肪增加的情况下,中性内肽酶缺乏小鼠血糖状态的改善与活性GLP-1水平升高、血浆DPP-4活性降低和β细胞功能改善有关。因此,抑制中性内肽酶可能是2型糖尿病的一种新治疗策略。